G Raghu

Summary

Affiliation: University of Washington
Country: USA

Publications

  1. ncbi request reprint Idiopathic pulmonary fibrosis: current trends in management
    Ganesh Raghu
    University of Washington Medical Center, 1959 N E Pacific, Campus Box 356522, Seattle, WA 98195 6522, USA
    Clin Chest Med 25:621-36, v. 2004
  2. ncbi request reprint Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis
    Talmadge E King
    Department of Medicine, San Francisco General Hospital, University of California at San Francisco, San Francisco, CA 94110, USA
    Chest 127:171-7. 2005
  3. ncbi request reprint Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: a case series
    Ganesh Raghu
    Division of Pulmonary and Critical Care Medicine, University of Washington Medical Center, 1959 NE Pacific, Campus Box 356522, Seattle, WA 98195 6522, USA
    Chest 129:794-800. 2006
  4. doi request reprint Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials
    Ganesh Raghu
    Division of Pulmonary and Critical Care Medicine, Campus Box 356175, University of Washington, Seattle, WA 98195, USA
    Am J Respir Crit Care Med 185:1044-8. 2012
  5. ncbi request reprint The accuracy of the clinical diagnosis of new-onset idiopathic pulmonary fibrosis and other interstitial lung disease: A prospective study
    G Raghu
    Department of Medicine, University of Washington, Seattle, WA, USA
    Chest 116:1168-74. 1999
  6. pmc The epidemiology of interstitial lung disease and its association with lung cancer
    G Raghu
    Department of Medicine, University of Washington Medical Center, Campus Box 356522, Seattle, WA 98195 6522, USA
    Br J Cancer 91:S3-10. 2004
  7. pmc Quality of life and dyspnoea in patients treated with bosentan for idiopathic pulmonary fibrosis (BUILD-1)
    G Raghu
    Division of Pulmonary and Critical Care Medicine, University of Washington School of Medicine, Seattle, WA 98195 6522, USA
    Eur Respir J 35:118-23. 2010
  8. ncbi request reprint Interstitial lung disease: clinical evaluation and keys to an accurate diagnosis
    Ganesh Raghu
    Departments of Medicine and Laboratory Medicine, University of Washington Medical Center, 1959 East Pacific, Campus Box 356522, Seattle, WA 91895 6522, USA
    Clin Chest Med 25:409-19, v. 2004
  9. ncbi request reprint High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis
    G Raghu
    Division of Pulmonary and Critical Care Medicine, University of Washington, Seattle, WA 98195, USA
    Eur Respir J 27:136-42. 2006
  10. ncbi request reprint A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis
    Ganesh Raghu
    Division of Pulmonary Medicine, University of Washington, Seattle 98195, USA
    N Engl J Med 350:125-33. 2004

Research Grants

Detail Information

Publications38

  1. ncbi request reprint Idiopathic pulmonary fibrosis: current trends in management
    Ganesh Raghu
    University of Washington Medical Center, 1959 N E Pacific, Campus Box 356522, Seattle, WA 98195 6522, USA
    Clin Chest Med 25:621-36, v. 2004
    ..It is hoped that ongoing molecular genetic studies and results of clinical trials will improve outcome of patients and families affected with this disease in the near future...
  2. ncbi request reprint Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis
    Talmadge E King
    Department of Medicine, San Francisco General Hospital, University of California at San Francisco, San Francisco, CA 94110, USA
    Chest 127:171-7. 2005
    ..Idiopathic pulmonary fibrosis (IPF) is a devastating disease, yet validated, reliable criteria for evaluating patient response to therapies in clinical trials are lacking...
  3. ncbi request reprint Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: a case series
    Ganesh Raghu
    Division of Pulmonary and Critical Care Medicine, University of Washington Medical Center, 1959 NE Pacific, Campus Box 356522, Seattle, WA 98195 6522, USA
    Chest 129:794-800. 2006
    ..Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease despite the available treatment regimes. Increased acid gastroesophageal reflux (GER) occurs in IPF patients...
  4. doi request reprint Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials
    Ganesh Raghu
    Division of Pulmonary and Critical Care Medicine, Campus Box 356175, University of Washington, Seattle, WA 98195, USA
    Am J Respir Crit Care Med 185:1044-8. 2012
    ..For patients with IPF, there are currently no validated surrogate endpoints...
  5. ncbi request reprint The accuracy of the clinical diagnosis of new-onset idiopathic pulmonary fibrosis and other interstitial lung disease: A prospective study
    G Raghu
    Department of Medicine, University of Washington, Seattle, WA, USA
    Chest 116:1168-74. 1999
    ..The accuracy of a clinical diagnosis of IPF and other subsets of ILD has never been established in prospective studies. We investigated the accuracy and validity of a clinical diagnosis of IPF and ILD other than IPF...
  6. pmc The epidemiology of interstitial lung disease and its association with lung cancer
    G Raghu
    Department of Medicine, University of Washington Medical Center, Campus Box 356522, Seattle, WA 98195 6522, USA
    Br J Cancer 91:S3-10. 2004
    ..In this review, we examine the epidemiology of ILD and the basis for its association with lung cancer...
  7. pmc Quality of life and dyspnoea in patients treated with bosentan for idiopathic pulmonary fibrosis (BUILD-1)
    G Raghu
    Division of Pulmonary and Critical Care Medicine, University of Washington School of Medicine, Seattle, WA 98195 6522, USA
    Eur Respir J 35:118-23. 2010
    ..Observations from exploratory analyses suggested benefits of bosentan on HRQoL among patients who had undergone surgical lung biopsy for diagnosis, and they merit further investigation...
  8. ncbi request reprint Interstitial lung disease: clinical evaluation and keys to an accurate diagnosis
    Ganesh Raghu
    Departments of Medicine and Laboratory Medicine, University of Washington Medical Center, 1959 East Pacific, Campus Box 356522, Seattle, WA 91895 6522, USA
    Clin Chest Med 25:409-19, v. 2004
    ..This article discusses the importance and essentials of clinical evaluation and keys to an accurate diagnosis of interstitial lung disease...
  9. ncbi request reprint High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis
    G Raghu
    Division of Pulmonary and Critical Care Medicine, University of Washington, Seattle, WA 98195, USA
    Eur Respir J 27:136-42. 2006
    ....
  10. ncbi request reprint A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis
    Ganesh Raghu
    Division of Pulmonary Medicine, University of Washington, Seattle 98195, USA
    N Engl J Med 350:125-33. 2004
    ..Idiopathic pulmonary fibrosis is a progressive, fatal disease with no known efficacious therapy...
  11. ncbi request reprint Incidence and prevalence of idiopathic pulmonary fibrosis
    Ganesh Raghu
    University of Washington Medical Center, Seattle, WA 98195 6522, USA
    Am J Respir Crit Care Med 174:810-6. 2006
    ..Idiopathic pulmonary fibrosis is a chronic interstitial lung disease of unknown etiology; its epidemiology in the United States has not been well characterized...
  12. doi request reprint Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial
    Ganesh Raghu
    Division of Pulmonary and Critical Care Medicine, Campus Box 356175, University of Washington, Seattle, WA 98195 6522, USA
    Am J Respir Crit Care Med 178:948-55. 2008
    ..An efficacious medical therapy for idiopathic pulmonary fibrosis (IPF) remains elusive...
  13. doi request reprint Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial
    Talmadge E King
    Department of Medicine, University of California San Francisco, San Francisco, CA 94143 0120, USA
    Lancet 374:222-8. 2009
    ..We assessed whether treatment with interferon gamma-1b improved survival compared with placebo in patients with idiopathic pulmonary fibrosis and mild-to-moderate impairment of pulmonary function...
  14. ncbi request reprint The timed walk test as a measure of severity and survival in idiopathic pulmonary fibrosis
    T S Hallstrand
    Dept of Medicine, Division of Pulmonary and Critical Care Medicine, University of Washington, Seattle, WA 98195 6522, USA
    Eur Respir J 25:96-103. 2005
    ..In unadjusted logistic regression models, odds of death at 2 yrs were associated with the same parameters. In conclusion, the timed walk test relates to disease severity and long-term outcome in progressive idiopathic pulmonary fibrosis...
  15. doi request reprint Bronchoalveolar lavage for the evaluation of interstitial lung disease: is it clinically useful?
    K C Meyer
    Division of Pulmonary and Critical Care Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
    Eur Respir J 38:761-9. 2011
    ..This perspective reviews the current status of using BAL as a diagnostic tool for the diagnosis of ILD...
  16. ncbi request reprint BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis
    Talmadge E King
    Department of Medicine, UCSF, 505 Parnassus Avenue, Room M994, San Francisco, CA 94110, USA
    Am J Respir Crit Care Med 177:75-81. 2008
    ..Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal lung disease lacking effective treatment...
  17. pmc Acute constrictive pericarditis after lung transplantation for lymphangioleiomyomatosis
    Martha E Billings
    Department of Medicine, University of Washington, Seattle, Washington 98104, USA
    J Heart Lung Transplant 28:110-3. 2009
    ..This represents a novel complication likely due to progression of extrapulmonary LAM and should be considered in LAM transplant patients with dyspnea...
  18. ncbi request reprint Lung allocation score for lung transplantation: impact on disease severity and survival
    Cynthia J Gries
    Division of Pulmonary and Critical Care Medicine, University of Washington, Seattle, WA 98195, USA
    Chest 132:1954-61. 2007
    ..The impact of LAS implementation on patient characteristics and survival is unknown...
  19. ncbi request reprint Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?
    Kevin R Flaherty
    Division of Pulmonary and Critical Care Medicine, Department of Radiology, University of Michigan Health System, 3916 Taubman Center, 1500 E Medical Center Drive, Ann Arbor, MI 48109 0360, USA
    Am J Respir Crit Care Med 170:904-10. 2004
    ..We conclude that dynamic interactions between clinicians, radiologists, and pathologists improve interobserver agreement and diagnostic confidence...
  20. ncbi request reprint High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy
    Ajit P Limaye
    Department of Laboratory Medicine, University of Washington, Seattle, WA, USA
    J Infect Dis 185:20-7. 2002
    ..All ganR isolates contained a UL97 mutation. GanR CMV infection occurs in nearly 10% of lung transplant recipients, despite preemptive antiviral therapy, and is more common among D+/R- patients...
  21. doi request reprint DAS181 treatment of severe parainfluenza type 3 pneumonia in a lung transplant recipient
    D R Drozd
    Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington 98195 6175, USA
    Transpl Infect Dis 15:E28-32. 2013
    ..Treatment was well tolerated and associated with improvement in oxygenation and symptoms, along with rapid clearance of PIV. DAS181 should be systematically evaluated for treatment of PIV infection in transplant recipients...
  22. pmc Acute exacerbations of idiopathic pulmonary fibrosis
    Harold R Collard
    Department of Medicine, San Francisco General Hospital, University of California, USA
    Am J Respir Crit Care Med 176:636-43. 2007
    ..The potential pathobiological roles of infection, disordered cell biology, coagulation, and genetics are discussed, and future research directions are proposed...
  23. ncbi request reprint The role of gastroesophageal reflux in idiopathic pulmonary fibrosis
    Ganesh Raghu
    University of Washington Medical Center, Seattle 98195 6522, USA
    Am J Med 115:60S-64S. 2003
    ....
  24. doi request reprint Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial
    M A Judson
    Division of Pulmonary and Critical Care Medicine, Medical University of South Carolina, Charleston, SC, USA
    Eur Respir J 31:1189-96. 2008
    ..Infliximab may be beneficial compared with placebo in the treatment of extrapulmonary sarcoidosis in patients already receiving corticosteroids, as assessed by the severity tool described in the present study...
  25. ncbi request reprint Invasive pneumococcal infections in adult lung transplant recipients
    Guy de Bruyn
    Department of Medicine, University of Washington, Washington, WA, USA
    Am J Transplant 4:1366-71. 2004
    ..Alternative prevention strategies, including use of the conjugated pneumococcal vaccine, should be explored in future studies...
  26. doi request reprint Assessment of current practice in the diagnosis and therapy of idiopathic pulmonary fibrosis
    T Peikert
    Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Mayo Building East 18, Rochester, MN, USA
    Respir Med 102:1342-8. 2008
    ..Acceptance and implementation of these guidelines have not been assessed. We surveyed the fellows of the American College of Chest Physicians (FCCP) to establish current practice patterns regarding the diagnosis and therapy of IPF...
  27. pmc A critical assessment of treatment options for idiopathic pulmonary fibrosis
    Nirav R Shah
    Department of Medicine, New York University School of Medicine, New York, NY, USA
    Sarcoidosis Vasc Diffuse Lung Dis 22:167-74. 2005
    ..We sought to formally review available evidence on treatment options for IPF and to have a diverse panel of physicians rate the "appropriateness," "inappropriateness," or "uncertainty" of some of the available therapeutic options...
  28. doi request reprint Imaging of thoracic lymphatic diseases
    Siva P Raman
    Department of Radiology, University of Washington Medical Center, Seattle, WA 98195, USA
    AJR Am J Roentgenol 193:1504-13. 2009
    ....
  29. pmc Does chronic microaspiration cause idiopathic pulmonary fibrosis?
    Joyce S Lee
    Department of Medicine, University of California, San Francisco, CA, USA
    Am J Med 123:304-11. 2010
    ..Defining the role of chronic microaspiration in idiopathic pulmonary fibrosis is essential as it has potential clinical, pathobiological, and treatment implications for this deadly disease...
  30. ncbi request reprint Inherited interstitial lung disease
    Christine Kim Garcia
    Eugene McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center, Building NB10 210A, Mail Code 8591, Dallas, TX 75390, USA
    Clin Chest Med 25:421-33, v. 2004
    ..The reader is directed to recent reviews on human genetic predisposition of sarcoidosis, environmental-related, drug-related, connective tissue related pulmonary fibrosis, and genetic predisposition of fibrosis in animal models...
  31. pmc Adult-onset pulmonary fibrosis caused by mutations in telomerase
    Kalliopi D Tsakiri
    McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA
    Proc Natl Acad Sci U S A 104:7552-7. 2007
    ..Thus, mutations in TERT or TERC that result in telomere shortening over time confer a dramatic increase in susceptibility to adult-onset IPF...
  32. ncbi request reprint Medical treatment for pulmonary fibrosis: current trends, concepts, and prospects
    Kevin K Brown
    Interstitial Lung Disease Program, National Jewish Medical and Research Center, Denver, CO, USA
    Clin Chest Med 25:759-72, vii. 2004
    ..The necessary, and desperately needed, next generation of therapies, focused on specific molecular targets thought to play pivotal roles in the development and progression of fibrosis, are under active investigation...
  33. ncbi request reprint High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis
    David A Lynch
    Department of Radiology, and Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, Box A030, Room 2233 Denver, CO 80262, USA
    Am J Respir Crit Care Med 172:488-93. 2005
    ..High-resolution computed tomography (HRCT) is an integral aspect of the evaluation of patients with suspected idiopathic pulmonary fibrosis (IPF). However, few studies have evaluated its use in a large cohort...
  34. ncbi request reprint The clinical course of patients with idiopathic pulmonary fibrosis
    Fernando J Martinez
    University of Michigan, Ann Arbor, Michigan 48109, USA
    Ann Intern Med 142:963-7. 2005
    ..Prospective data defining the clinical course in idiopathic pulmonary fibrosis (IPF) are sparse...
  35. pmc Telomere shortening in familial and sporadic pulmonary fibrosis
    Jennifer T Cronkhite
    Eugene McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center, Dallas, TX 75390 8591, USA
    Am J Respir Crit Care Med 178:729-37. 2008
    ..Heterozygous mutations in the coding regions of the telomerase genes, TERT and TERC, have been found in familial and sporadic cases of idiopathic interstitial pneumonia. All affected patients with mutations have short telomeres...
  36. doi request reprint Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project
    William D Travis
    Attending Thoracic Pathologist, Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Am J Respir Crit Care Med 177:1338-47. 2008
    ..Concern was expressed that NSIP was a "wastebasket" category, difficult to distinguish from other idiopathic interstitial pneumonias...
  37. ncbi request reprint Bronchoalveolar cellular analysis in scleroderma lung disease: does Sutton's law hold?
    Robert P Baughman
    Am J Respir Crit Care Med 177:2-3. 2008
  38. pmc Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?
    Kevin R Flaherty
    University of Michigan Health System, Ann Arbor, MI 48109 0360, USA
    Am J Respir Crit Care Med 175:1054-60. 2007
    ..Treatment and prognoses of diffuse parenchymal lung diseases (DPLDs) varies by diagnosis. Obtaining a uniform diagnosis among observers is difficult...

Research Grants3

  1. Clinical Center for an Idiopathic Pulmonary Fibrosis Cl*
    Ganesh Raghu; Fiscal Year: 2007
    ..End of Abstract) ..